Lilly signs 'Happy Gilmore 2' actress Kym Whitley as Zepbound patient spokesperson

Eli Lilly has brought actress Kym Whitley, who appears in this summer's "Happy Gilmore 2," on board as a patient spokesperson for Zepbound, the company's tirzepatide medicine for obesity ^[1]. The partnership was reported on July 21, 2025 ^[1].

Whitley describes her experience with the drug in a question-and-answer piece on Lilly's website for Zepbound, where her account appears alongside stories from other patients ^[1]. According to the report, she appears to be Lilly's first official celebrity spokesperson for the weight-loss medication ^[1]. The report does not say whether she is paid or what the arrangement is worth; those terms have not been disclosed ^[1].

Whitley, an Emmy-nominated actress who has worked since the late 1980s, has appeared in "Deliver Us From Eva," "Young & Hungry" and "The Bay," and has hosted talk shows, game shows and her own reality series, "Raising Whitley" ^[1]. In the sequel to the 1996 comedy, she acts opposite Adam Sandler ^[1]. During the press tour she also spoke with People magazine about the part Zepbound has played in her weight loss over the past year ^[1].

In the Q&A, she said she "hit a wall" after years of trying different ways to manage her weight, and that hearing about Zepbound from friends led her to ask her doctor about it ^[1]. "What helped me break that cycle of weight loss and regain was having a tool like Zepbound that supported the changes I was already making with diet and exercise," she said ^[1]. She added that managing obesity is hard but that "support is out there" ^[1].

She repeated the drug's label instructions, describing the medicine as a tool rather than a quick solution: "You still have to do the work. You still have to eat right, get your nutrients in, and move your body" ^[1]. Zepbound's FDA label specifies that it is meant to be used alongside a reduced-calorie diet and increased physical activity ^[1].

Lilly's other tirzepatide product, Mounjaro, was the subject of a separate campaign in May 2025 featuring "Modern Family" actor Eric Stonestreet, who appeared with his mother, Jamey, to talk about their Type 2 diabetes and Mounjaro's A1C-lowering benefits ^[1]. Mounjaro came first and is approved as a diabetes medicine ^[1]. On price, Lilly recently added single-dose vials of Zepbound's highest dose strengths at $499 a month through its LillyDirect pharmacy ^[1].

Why it matters for patients

Zepbound reaches the public mostly through prescriptions and pharmacy counters, but a movie press tour puts the drug's name in front of audiences that may not be reading about obesity treatment. The report frames the Whitley arrangement as marketing rather than new clinical evidence, and no new study results are attached to it ^[1].

The concrete consumer detail in the report is cost: $499 a month for single-dose vials of the highest dose strengths, sold through LillyDirect ^[1]. That figure was current when the partnership was announced, and it applies to those specific vial offerings, not to every version or dose of the drug ^[1].

The message Whitley delivered matches the label language Lilly repeats in the Q&A, which says the medicine is intended for use with diet and exercise rather than on its own ^[1]. Her stated goal is to encourage open discussion of obesity as a disease and reduce the stigma around it ^[1].

Several things are not established. The report does not say how much weight Whitley lost, how long she has been taking Zepbound, or whether celebrity spokespeople affect what patients ask their doctors about. None of that has been reported ^[1]. GLP-1 medications other than Zepbound are not part of this partnership ^[1].

What happens next

Lilly has not said how long the Whitley partnership will run or what else it includes ^[1]. "Happy Gilmore 2" is described as upcoming, and the report does not give its release date ^[1]. The $499 monthly price for the highest-dose single-dose vials through LillyDirect is the figure cited at the time of the announcement ^[1].